LLY

1,130.08

+0.44%↑

JNJ

232.65

+1.91%↑

ABBV

227.34

+1.09%↑

UNH

400.31

+0.89%↑

MRK

120.93

+0.57%↑

LLY

1,130.08

+0.44%↑

JNJ

232.65

+1.91%↑

ABBV

227.34

+1.09%↑

UNH

400.31

+0.89%↑

MRK

120.93

+0.57%↑

LLY

1,130.08

+0.44%↑

JNJ

232.65

+1.91%↑

ABBV

227.34

+1.09%↑

UNH

400.31

+0.89%↑

MRK

120.93

+0.57%↑

LLY

1,130.08

+0.44%↑

JNJ

232.65

+1.91%↑

ABBV

227.34

+1.09%↑

UNH

400.31

+0.89%↑

MRK

120.93

+0.57%↑

LLY

1,130.08

+0.44%↑

JNJ

232.65

+1.91%↑

ABBV

227.34

+1.09%↑

UNH

400.31

+0.89%↑

MRK

120.93

+0.57%↑

Kodu・Aktsiate loetelu・Emergent BioSolutions Inc

Emergent BioSolutions Inc

Suletud

SektorTervishoid

8.08 -3.81

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

7.93

Max

8.47

Põhinäitajad
By Trading Economics
Sissetulek	61M 6.8M
Müük	7.4M 156M
P/E Sektori keskmine	8.634 49.888
Aktsiakasum	0.21
Kasumimarginaal	4.356
Töötajad	900
EBITDA	28M 35M

Soovitused
By TipRanks
Soovitused	Osta
12 kuu keskmine prognoos	+42.18% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	5. aug 2026

Turustatistika
By TradingEconomics
Turukapital	23M 438M
Eelmine avamishind	11.89
Eelmine sulgemishind	8.08

Uudiste sentiment

By Acuity

93%

2 / 344 Pingereas Healthcare

Emergent BioSolutions Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

5. juuni 2026, 19:20 UTC

Suurimad hinnamuutused turgudel

Meta Platforms Slips on Report of Plans for Multibillion-Dollar Offering to Fund AI Buildout

5. juuni 2026, 21:27 UTC

Tulu

Carnage in Chip Stocks Hits Extra Hard in Top-Heavy Market -- WSJ

5. juuni 2026, 20:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

5. juuni 2026, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

5. juuni 2026, 20:20 UTC

Omandamised, ülevõtmised, äriostud

Altice France Group Had Granted Initial Exclusivity Period to Consortium Until May 15, Which Was Then Extended to June 5

5. juuni 2026, 20:19 UTC

Omandamised, ülevõtmised, äriostud

Altice France Group, Bouygues Telecom, Free-iliad Group, Orange Exclusivity Period Extended by 48 Hours

5. juuni 2026, 20:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

5. juuni 2026, 19:26 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

5. juuni 2026, 19:26 UTC

Market Talk

Hog Futures Tumble to Close Week -- Market Talk

5. juuni 2026, 19:10 UTC

Market Talk

Canada's GDP Targets From AI-Related Spending Require Second Look -- Market Talk

5. juuni 2026, 19:03 UTC

Market Talk

Oil Falls As Market Holds Out Hope for End to Conflict -- Market Talk

5. juuni 2026, 18:59 UTC

Market Talk

U.S. Natural-Gas Futures Pull Back After Gains -- Market Talk

5. juuni 2026, 18:47 UTC

Market Talk

Canada's Labor Market 'Retains Some Weakness' Despite Stellar May Report -- Market Talk

5. juuni 2026, 18:34 UTC

Market Talk

Hyperliquid ETFs Have Inflows Despite Crypto Weakness -- Market Talk

5. juuni 2026, 18:33 UTC

Omandamised, ülevõtmised, äriostud

The U.S. Government Could Take a Stake in OpenAI. What That Means for Tech Stocks. -- Barrons.com

5. juuni 2026, 17:50 UTC

Tulu

Lululemon Slumps on Earnings. Bargain Hunters Beware. -- Barrons.com

5. juuni 2026, 17:27 UTC

Market Talk

U.S. Oil Rig Count Rises for 6th Straight Week -- Market Talk

5. juuni 2026, 16:48 UTC

Omandamised, ülevõtmised, äriostud

Ryan Cohen Is Ready to Talk About eBay. For Real. -- Barrons.com

5. juuni 2026, 16:20 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

5. juuni 2026, 16:20 UTC

Market Talk

Financial Services Roundup: Market Talk

5. juuni 2026, 16:20 UTC

Market Talk

Health Care Roundup: Market Talk

5. juuni 2026, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

5. juuni 2026, 15:44 UTC

Omandamised, ülevõtmised, äriostud

Ryan Cohen Is Ready to Talk About eBay. For Real. -- Barrons.com

5. juuni 2026, 15:26 UTC

Market Talk

Gold Down Nearly 3% On Rate Hike Concerns After U.S. Hiring Data -- Market Talk

5. juuni 2026, 15:25 UTC

Tulu

Quantinuum Trades Below Offer Price. Why the Quantum Stock Is Sliding. -- Barrons.com

5. juuni 2026, 15:16 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

5. juuni 2026, 15:16 UTC

Market Talk

Zcash Tumbles After Exploit Found -- Market Talk

5. juuni 2026, 15:09 UTC

Market Talk

Canada's May Jobs Report Underscores Volatility Worries Over Data Collection -- Market Talk

5. juuni 2026, 15:07 UTC

Market Talk

Canada's Economy Still Has Legs With Total Employment Close to Record -- Market Talk

5. juuni 2026, 15:05 UTC

Market Talk

Canada's Labor-Market Weakness to Start 2026 Likely 'Overstated' -- Market Talk

Võrdlus sarnastega

Hinnamuutus

Emergent BioSolutions Inc Prognoos

Hinnasiht

By TipRanks

42.18% tõus

12 kuu keskmine prognoos

Keskmine 12 USD 42.18%

Kõrge 12 USD

Madal 12 USD

Põhineb 1 Wall Streeti analüütiku instrumendi Emergent BioSolutions Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

1 ratings

Osta

Hoia

Müü

Põhineb 1 analüütiku instrumendi Emergent BioSolutions Inc aktsia reitingul - viimase 3 kuu andmed.

Sentiment

By Acuity

2 / 344 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Emergent BioSolutions Inc

Emergent BioSolutions Inc., a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax. It also provides ACAM2000, a smallpox vaccine; CNJ-016 to address complications from smallpox vaccination; TEMBEXA for the treatment of smallpox disease caused by variola virus in adult and pediatric patients; BAT for the treatment of symptomatic botulism; Ebanga for the treatment of Ebola; Reactive Skin Decontamination Lotion Kit to remove or neutralize chemical warfare agents from the skin; Trobigard, a atropine sulfate obidoxime chloride auto-injector. In addition, the company is developing CGRD-001 for the treatment of poisoning by organophosphorus nerve agents or organophosphorus compounds; EBS-LASV to prevent Lassa fever; EBS-MARV to prevent Marburg virus disease; EBS-SUDV to prevent Sudan virus disease; Pan-Ebola mAbs for the treatment of ebola virus; SIAN Antidote for initial treatment of certain or suspected acute cyanide poisoning; UniFlu for immunity against influenza A and B viruses; and WEVEE-VLP for equine encephalitis virus infections. Further, it provides contract development and manufacturing services comprising drug substance and product manufacturing, and packaging, as well as technology transfer, process, and analytical development services. The company was incorporated in 1998 and is headquartered in Gaithersburg, Maryland.